文献速递银屑病与炎症性皮肤病

皮下注射甲氨蝶呤治疗中重度银屑病患者:一项批判性评价

Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal.
PubMed 文献 · Br J Dermatol · 2018-05-09

Warren等开展前瞻性、双盲、随机(3:1)、安慰剂对照研究,在德国、法国、荷兰和英国16个中心纳入120例中重度慢性斑块状银屑病成人患者。第16周时,甲氨蝶呤组41%的患者达到PASI 75,安慰剂组为10%(相对风险3.93,95%置信区间1.31-11.81;P=0.0026)。作者结论为皮下注射甲氨蝶呤52周风险-获益特征良好。

要点

  • 第16周PASI 75:甲氨蝶呤组41% vs 安慰剂组10%(相对风险3.93,95%置信区间1.31-11.81;P=0.0026)。
  • 皮下注射甲氨蝶呤总体耐受良好,52周研究期间无与该治疗相关的严重不良事件。
  • 作者结论为皮下注射甲氨蝶呤在银屑病患者中52周风险-获益特征良好。

核心结论

  • Warren等结论为皮下注射甲氨蝶呤在银屑病患者中52周风险-获益特征良好。

研究设计与样本

  • 前瞻性、双盲、随机(3:1)、安慰剂对照研究,在德国、法国、荷兰和英国16个中心开展。
  • 纳入基线前至少6个月诊断为中重度慢性斑块状银屑病且未用过甲氨蝶呤的成人患者,共120例。
  • 第一阶段随机接受每周皮下注射甲氨蝶呤起始剂量17.5 mg或安慰剂,共16周;第8周未达到PASI 50者剂量升至每周22.5 mg。
  • 治疗联合每周5 mg叶酸。
  • 第一阶段后为16至52周开放标签期(第二阶段),两组均接受每周甲氨蝶呤注射;第24周未达到PASI 50者可剂量升至每周22.5 mg。

主要发现

  • 第16周达到PASI 75的患者比例:甲氨蝶呤组41% vs 安慰剂组10%(相对风险3.93,95%置信区间1.31-11.81;P=0.0026)。
  • 皮下注射甲氨蝶呤总体耐受良好,52周研究期间无与该治疗相关的严重不良事件。
  • 患者大多为中老年白人男性,银屑病病程长,平均体重指数30.1 kg m-2。

关键数值与推荐

  • 主要结局为第16周达到PASI 75的患者比例。
  • 银屑病严重程度采用PASI测量,另用两种银屑病严重程度指标和两种生活质量指标,并分析安全性指标。
  • 亚研究分析基线和第16周配对皮肤活检(组织病理学、免疫组化及白细胞介素-17A、干扰素-γ和肿瘤坏死因子-α表达)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Warren et al. set out to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate-to-severe chronic plaque psoriasis. SETTING AND DESIGN: This was a prospective, double-blind, randomized (3 : 1), placebo-controlled study, conducted across 16 centres in Germany, France, the Netherlands and the U.K. STUDY EXPOSURE: Methotrexate-naive adults with a diagnosis of moderate-to-severe chronic plaque psoriasis for at least 6 months before baseline were randomly assigned to receive weekly subcutaneous injections of either methotrexate at a starting dose of 17·5 mg, or placebo for 16 weeks (first phase). Dose escalation to 22·5 mg per week was implemented after 8 weeks if patients did not achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50). Treatment was combined with folic acid 5 mg per week. The first phase of the study was followed by an open-label period from 16 to 52 weeks (second phase), in which both groups received weekly methotrexate injections. At week 24, dose escalation to 22·5 mg per week was possible in patients not achieving PASI 50. OUTCOMES: Psoriasis severity was measured using PASI. The authors also used two other psoriasis severity measures and two quality-of-life measures, looked at safety indices and performed a substudy analysing paired skin biopsies at baseline and week 16 (histopathology, immunohistochemistry and expression of interleukin-17A, interferon-γ and tumour necrosis factor-α). PRIMARY OUTCOME MEASURES: The primary outcome was the proportion of patients reaching PASI 75 at week 16. RESULTS: In total 120 patients were included in this trial, most of whom were middle-aged white men with long-standing psoriasis, and the mean body mass index was 30·1 kg m-2 . PASI 75 was achieved in 41% of patients receiving methotrexate vs. 10% of patients receiving placebo (relative risk 3·93, 95% confidence interval 1·31-11·81; P = 0·0026) at week 16. Subcutaneous methotrexate was generally well tolerated, with no serious adverse events related to this treatment over the 52-week study. CONCLUSION: Warren et al. conclude that the 52-week risk-benefit profile of subcutaneous methotrexate is favourable in patients with psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Tsakok T, Jabbar-Lopez ZK, Smith CH, et al. Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal. Br J Dermatol. 2018. PMID: 29399784. doi:10.1111/bjd.16424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。